Sale of its blockbuster arthritis drug, Remicade, was particularly impacted by the rising influence of biosimilars, especially in the international markets. It needs to be seen how much the company has resisted this trend in the first quarter https://news.alphastreet.com/will-biosimilars-play-spoilsport-in-johnson-johnson-earnings/
